Other news to note
Thursday, February 20, 2014
Active Biotech AB, of Lund, Sweden, said partner Teva Pharmaceutical Industries Ltd., of Jerusalem, decided not to proceed to the randomization stage of the planned Libretto trial for Laquinimod (nerventra), an oral immunomodulator, in the treatment of relapsing remitting multiple sclerosis (RRMS), as the current design is no longer aligned with the regulatory strategy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.